LYSAKER, NORWAY--(Marketwire - April 15, 2008) - Pronova BioPharma ASA (OSE: PRON.OL) ("Pronova BioPharma" or "the company") has, with effect from 1 January 2008, changed the amortisation profiles within the estimated total useful life period for patents, customer contracts and customer relations acquired in the business combination in May 2006. Estimated amortisation charges of identifiable intangible assets in 2008, after updated amortisation profiles are NOK 94.4 million. The assessed useful lives of these intangible assets are unchanged. The residual values, useful lives and the amortisation methods applied are subject to review on an annual basis.
